GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyprotex PLC (LSE:CRX) » Definitions » ROC %

Cyprotex (LSE:CRX) ROC % : 32.51% (As of Jun. 2016)


View and export this data going back to 2002. Start your Free Trial

What is Cyprotex ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Cyprotex's annualized return on capital (ROC %) for the quarter that ended in Jun. 2016 was 32.51%.

As of today (2024-05-11), Cyprotex's WACC % is 0.00%. Cyprotex's ROC % is 0.00% (calculated using TTM income statement data). Cyprotex earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Cyprotex ROC % Historical Data

The historical data trend for Cyprotex's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyprotex ROC % Chart

Cyprotex Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.49 3.29 4.73 -41.61 21.93

Cyprotex Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.00 -67.85 7.75 38.98 32.51

Cyprotex ROC % Calculation

Cyprotex's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2015 is calculated as:

ROC % (A: Dec. 2015 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2014 ) + Invested Capital (A: Dec. 2015 ))/ count )
=1.976 * ( 1 - 0.55% )/( (9.457 + 8.465)/ 2 )
=1.965132/8.961
=21.93 %

where

Cyprotex's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2016 is calculated as:

ROC % (Q: Jun. 2016 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2015 ) + Invested Capital (Q: Jun. 2016 ))/ count )
=2.99 * ( 1 - 9% )/( (8.465 + 8.276)/ 2 )
=2.7209/8.3705
=32.51 %

where

Note: The Operating Income data used here is two times the semi-annual (Jun. 2016) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyprotex  (LSE:CRX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cyprotex's WACC % is 0.00%. Cyprotex's ROC % is 0.00% (calculated using TTM income statement data). Cyprotex earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Cyprotex ROC % Related Terms

Thank you for viewing the detailed overview of Cyprotex's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyprotex (LSE:CRX) Business Description

Traded in Other Exchanges
N/A
Address
Cyprotex PLC was incorporated on October 25, 2001. The Company together with its subsidiaries, provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity and pharmacokinetics) information to a number of different industries including the Pharmaceutical, Biotechnology, Cosmetic, Personal Care, Agrochemical, Chemical Industries and Academia. It provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. The Company operates in North America, Mainland Europe and United Kingdom.

Cyprotex (LSE:CRX) Headlines

No Headlines